Docstoc

Investor Notice: The Rosen Law Firm Announces Filing of Securities Class Action Against Arena Pharmaceuticals, Inc. - ARNA

Document Sample
Investor Notice: The Rosen Law Firm Announces Filing of Securities Class Action Against Arena Pharmaceuticals, Inc. - ARNA Powered By Docstoc
					Investor Notice: The Rosen Law Firm Announces
Filing of Securities Class Action Against Arena
Pharmaceuticals, Inc. - ARNA
September 22, 2010 06:32 PM Eastern Daylight Time  

NEW YORK--(EON: Enhanced Online News)--The Rosen Law Firm today announced that a class action lawsuit
has been filed on behalf of purchasers of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA - News) securities during
the period from March 30, 2009 through September 17, 2010. The complaint asserts claims against Arena
Pharmaceuticals and certain of its officers and directors for violations of the federal securities laws.

To join the class action against Arena Pharmaceuticals, go to the website at http://www.rosenlegal.com or call
Laurence Rosen, Esq. or Phillip Kim, Esq. toll-free at 866-767-3653. You may also email lrosen@rosenlegal.com
or pkim@rosenlegal.com for information on the class action.

The complaint alleges that the Company misled investors to believe that the pre-clinical and clinical trial data for its
developmental drug lorcaserin, or Lorqess, indicate it is a safe therapy for weight management.

On September 14, 2010, the FDA disclosed that lorcaserin caused cancer in rats in certain preclinical studies.

As a result of this adverse news, Arena shares declined from a close of $6.85 per share on September 13, 2010, to
close at $4.13 per share on September 14, a decline of $2.71 per share or approximately 40%. On September 16,
2010, the Wall Street Journal reported a federal advisory panel rejected lorcaserin. On September 17, 2010, Arena
shares declined an additional $1.99 per share or approximately 47%, causing investors substantial losses.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED,
YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO
REMAIN AN ABSENT CLASS MEMBER.

If you wish to join the class action or to discuss your ability to recover your investment losses, please contact
Laurence Rosen, Esq. or Phillip Kim, Esq. of The Rosen Law Firm toll-free at 866-767-3653 or via e-mail at
lrosen@rosenlegal.com or pkim@rosenlegal.com.

The Rosen Law Firm concentrates its practice on investor securities litigation, representing investors throughout the
world.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts
The Rosen Law Firm P.A.
Laurence Rosen, Esq., lrosen@rosenlegal.com
or
Phillip Kim, Esq., pkim@rosenlegal.com
212-686-1060
Weekends/After-hours: 917-797-4425
Toll Free: 1-866--767-3653
Fax: 212-202-3827
www.rosenlegal.com
Permalink: http://eon.businesswire.com/news/eon/20100922006901/en/Arena-
Pharmaceuticals/Lorcaserin/Lorqess

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:22
posted:9/22/2010
language:English
pages:2
Description: NEW YORK--(EON: Enhanced Online News)--The Rosen Law Firm Announces Filing of Securities Class Action Against Arena Pharmaceuticals, Inc. - ARNA a style='font-size
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.